Health Care & Life Sciences » Biotechnology | XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ADR | Income Statement

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
8,550.90
-
-
-
-
2,851
Cost of Goods Sold (COGS) incl. D&A
3,035.60
28.60
27.20
11.50
3.60
-
Gross Income
5,515.30
28.60
27.20
11.50
3.60
-
SG&A Expense
13,542.90
7,204.50
7,731.60
6,564.30
4,449.50
2,851
EBIT
8,027.60
7,233.10
7,758.80
6,575.80
4,453.10
2,851
Unusual Expense
6,204.70
-
6,231.90
3,255.30
2,751.70
13,399.50
Non Operating Income/Expense
3,844.10
361.30
46.60
88.30
1,136.60
100.70
Interest Expense
-
21.50
35.00
26.90
28.80
25.20
Pretax Income
10,352.10
7,580.10
14,072.30
9,769.70
2,809.20
10,735.50
Equity in Affiliates
3,050.00
-
-
-
-
-
Consolidated Net Income
13,402.10
7,580.10
14,072.30
9,769.70
2,809.20
10,735.50
Net Income
8,937.10
7,580.10
14,072.30
9,769.70
2,809.20
10,735.50
Net Income After Extraordinaries
8,937.10
6,120.60
11,395.30
9,769.70
2,809.20
10,735.50
Net Income Available to Common
8,937.10
9,039.60
14,072.30
9,769.70
2,809.20
10,735.50
EPS (Basic)
0.04
0.04
0.05
0.03
0.01
0.02
Basic Shares Outstanding
223,605.20
231,224.50
263,730.50
274,035.50
470,188.60
514,205.80
EPS (Diluted)
0.04
0.04
0.06
0.04
0.01
0.02
Diluted Shares Outstanding
223,605.20
231,224.50
263,730.50
274,035.50
470,188.60
514,205.80
EBITDA
6,901.40
7,204.50
7,731.60
6,564.30
4,449.50
-
Non-Operating Interest Income
36.10
35.80
-
-
57.60
312.80
Minority Interest Expense
4,465.00
-
-
-
-
-

About XTL Biopharmaceuticals

View Profile
Address
5 Badner Sreet
Ramat Gan HM 4365603
Israel
Employees -
Website http://www.xtlbio.com
Updated 07/08/2019
XTL Biopharmaceuticals Ltd is a biopharmaceutical company, which engages in the acquisition and development of pharmaceutical drugs. Its drug development program focuses on the treatment of systemic lupus erythematosus. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.